Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback